Once again, congressional lawmakers have introduced a bill that would end a practice that generic drug makers complain is used by brand-name rivals to thwart competition.
Known as the Fair Access for Safe and Timely Generics Act, the bipartisan legislation comes amid ongoing complaints that brand-name drug makers sometimes refuse to provide samples to generic companies. They need samples to prove their copycat versions are equivalent to brand-name drugs in order to win regulatory approval. The issue has also caught the eye of the Federal Trade Commission.
About the Author Reprints
